ArticleCells2026
Human Mesenchymal Stromal Cells Attenuate Hyperoxia-Induced Cellular Impairment of Immature Oligodendrocyte and Neurons.
Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mesenchymal Stem Cell (MSC)-based therapies for neonatal lung and brain injury - one size fits all?Molecular and cellular pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Preterm infants are at high risk of developing long-term brain injury such as encephalopathy of prematurity (EoP). Hyperoxia is a major contributor to EoP, affecting white and grey matter, with immature oligodendrocytes and hippocampal neurons being particularly vulnerable. While no causal therapy is available, mesenchymal stromal cells (MSCs) show therapeutic potential and are considered a promising candidate, although their effector mechanisms remain incompletely understood. Primary oligodendrocytes were isolated from mixed glial cultures of P0-P2 rats and hippocampal neurons from E16 rat embryos. On day 3 (oligodendrocytes) and day 5 (neurons) after isolation, cells were exposed to hyperoxia for 8 h and subsequently co-cultured indirectly with naive or hypoxic-preconditioned human MSCs (hMSCs) for 48 h under standard culture conditions. Degeneration, proliferation, differentiation and mitochondrial respiration were assessed in both cell types. Both naive and hypoxic-preconditioned hMSCs attenuated hyperoxia-induced degeneration, reduced proliferation and mitochondrial respiration failure. Although oligodendrocyte differentiation, assessed by myelin basic protein (MBP) expression, was modulated neither by hyperoxia nor by hMSC treatment, the dendritic structure in hippocampal neurons was impaired by hyperoxia and improved by hMSC treatment. Notably, hypoxic-preconditioned hMSCs showed a stronger therapeutic effect than naive hMSCs on hyperoxia-damaged hippocampal neurons. These findings indicate that indirect hMSC co-culture mitigates hyperoxia-induced impairment of immature oligodendrocytes and hippocampal neurons and that hypoxic preconditioning may modulate this effect in a cell type-specific manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.